The EORTC 1920 BIORADON team is pleased to announce that it has reached 300 participants and would like to thank patients and participating sites for their contribution, support and commitment to this study.
BIORADON is assessing the correlation between molecular profiles of non-small cell lung cancer patients and radon exposure. Radon has been the second most common carcinogen responsible for lung cancer after smoking and the first in non-smokers. In Europe, there are several radon-prone areas, however, indoor radon exposure has not yet been regulated. The European Cancer Prevention Code highlighted the importance of controlling radon exposure as one of the most efficient ways for cancer prevention.
BIORADON is a downstream project of the translational research SPECTA platform. Patients with lung cancer irrespective of stage and treatment agreed to donate blood and/or tissue for molecular analysis are eligible. After confirmation of eligibility they will receive two radon detectors need to be placed at their home for 3 months and answer a questionnaire. Cohorts of patients with driver mutations, driver fusions and without any driver aberrations will be studied and correlated with indoor radon concentration.
For more information please click here or contact the team at 1920@eortc.org .
The SPECTA platform is supported by Alliance Healthcare, a member of the AmerisourceBergen group.
